Top Markets
#1 Glidr Glidr +51.75%
#2 DOVU DOVU +48.17%
#3 Velvet Velvet +37.34%
#4 Black Phoenix Black Phoenix +34.06%
#5 Akedo Akedo +29.10%
#6 Cross Cross +27.01%
#7 Cap Cap +18.79%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.46%
#9 QANplatform QANplatform +14.35%
#10 Bitway Bitway +13.02%
Coin of the day
Glidr Glidr
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Enveric Biosciences, Inc. Enveric Biosciences, Inc.

Enveric Biosciences, Inc.

ENVB
Clasificación en acciones #38575
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse... Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Precio por acción
$1.48
Capitalización bursátil
$883.58K
Cambio (1 día)
-1.99%
Cambio (1 año)
-88.89%
País
US
Comercio Enveric Biosciences, Inc. (ENVB)

Categoría

Healthcare
Ganancias de Enveric Biosciences, Inc. (ENVB)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Enveric Biosciences, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Enveric Biosciences, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE